AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging
- 1 April 2007
- journal article
- research article
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 25 (3) , 319-327
- https://doi.org/10.1016/j.mri.2006.09.041
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumorsJournal of Clinical Oncology, 2004
- Vascular Endothelial Growth Factor as a Target for Anticancer TherapyThe Oncologist, 2004
- MRI for assessing antivascular cancer treatmentsThe British Journal of Radiology, 2003
- The impact of anti-angiogenic agents on cancer therapyZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Pathophysiologic basis of contrast enhancement in breast tumorsJournal of Magnetic Resonance Imaging, 1999
- Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictorsJournal of Magnetic Resonance Imaging, 1999
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- IntroductionCancer and Metastasis Reviews, 1990
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990